GBB

Headquartered in Hong Kong Science Park, Great Bay Bio is a high-tech enterprise dedicated to applying cutting-edge artificial intelligence technologies to drug development platforms. It upholds the vision of "making global bioprocess development simpler and more efficient," addressing numerous pain points such as low success rates, long cycles, and high costs in drug development. The company owns a 3,100-square-meter R&D laboratory building and has successfully advanced multiple biologics into the NDA stage, including Class I new drugs in China. Since its establishment, the company has accumulated extensive experimental data during the development of several national new drugs, creating an intelligent integrated database. Through deep learning, GBB aims to build a next-generation AI-powered drug R&D ecosystem. Three of its intelligent bioprocess development platforms have entered commercial operation: the intelligent cell line development platform Klone4.0™, the cell line stability prediction platform AlfaStaX®, and the intelligent media development platform AlfaMedX®. Great Bay Bio has been awarded the title of "National High-Tech Enterprise" twice by the Office of the National Leading Group for the Identification and Management of High-Tech Enterprises. It has also been recognized on VCBeat's "Top 150 Most Investment-Worthy Enterprises in China—New Bud List 2020," the "Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area" hosted by ZC Industry Research Institute and KPMG China and organized by Guangdong Medical Valley, and the "Top 15 of the 2021 Merck GBA Innovation Boot Camp" hosted by Merck.